Quarterly report pursuant to Section 13 or 15(d)

Intangibles Assets

v3.10.0.1
Intangibles Assets
9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Disclosure [Text Block]
6.
Intangibles Assets
 
Intangible assets at September 30, 2018 consist of the rights to trade-secrets and know-how related to the manufacturing of the
EyeGate Ocular Bandage Gel (“OBG”). During
the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care, Inc. (“SentrX”) with respect to certain rights relating to the manufacturing of the EyeGate OBG product. The intangible assets were recorded at $250,000, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified development and commercial milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. The Company capitalizes the intangible assets, amortizes them over the estimated useful life, and periodically evaluates the assets for impairment. The Company had no intangible assets at December 31, 2017.